Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. (OTCQX: VXRT) is a clinical-stage biotechnology company developing oral recombinant vaccines delivered as pills, and its news flow reflects progress across multiple vaccine programs and corporate developments. The company regularly issues updates on its clinical trials for oral pill vaccine candidates targeting coronavirus, norovirus and influenza, as well as a therapeutic HPV vaccine candidate that it identifies as its first immune-oncology program.
Readers following Vaxart news can expect detailed reports on clinical data from its oral vaccine platform. For example, the company has announced Phase 1 results for a bivalent norovirus pill vaccine in lactating women, describing safety, tolerability and increases in norovirus-specific IgA in serum and breast milk, along with evidence of norovirus-specific IgA in infant stool. Vaxart has also highlighted data from second-generation norovirus constructs showing stronger blocking antibody responses and robust fecal IgA increases, and has presented these findings at scientific conferences such as the International Calicivirus Conference, World Vaccine Congress and IDWeek.
Vaxart’s news also covers its COVID-19 oral pill vaccine program, including enrollment and follow-up in a large Phase 2b trial funded under a Project NextGen/BARDA contract, and regulatory and funding updates such as a stop work order that delimited certain activities while maintaining support for follow-up of enrolled participants. In addition, the company has reported on an exclusive, worldwide license and collaboration agreement with Dynavax Technologies Corporation for its oral COVID-19 vaccine candidate, outlining the structure of upfront payments, an equity investment, and potential milestones and royalties.
Beyond clinical and partnership news, Vaxart issues releases on corporate actions, including stock listing changes, governance matters and capital markets events such as conference presentations and investor calls. Investors and observers can use this news feed to track the evolution of Vaxart’s oral vaccine platform, key trial readouts, collaboration milestones and changes in its trading venue and cost management initiatives.
Vaxart (OTCQX: VXRT) will present clinical updates on its oral norovirus and COVID-19 pill vaccine programs at World Vaccine Congress Europe 2025 in Amsterdam on October 13–16, 2025. Two presentations by Dr. Sean Tucker will cover a bivalent oral norovirus vaccine with recent immunogenicity improvements and a clinical update on the oral COVID-19 vaccine covering Phase 1 to Phase 2 data.
The company highlights that its oral recombinant pill platform has generated both systemic and mucosal immune responses and shown a favorable safety and tolerability profile in clinical trials, positioning these programs as ongoing clinical-stage efforts toward potential global public-health solutions.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company specializing in oral recombinant pill vaccines, has announced the withdrawal of its reverse stock split proposal. CEO Steven Lo emphasized that the company will maintain frequent stockholder communication while focusing on advancing their oral pill vaccine platform technology.
The decision comes after receiving constructive feedback from stockholders, with management expressing commitment to creating long-term value through their proprietary vaccine delivery platform development.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant pill vaccines, has appointed W. Mark Watson as Lead Independent Director. Watson, a Certified Public Accountant with over 50 years of experience, including 40+ years at Deloitte, has served on Vaxart's Board since August 2022.
The company is implementing two significant governance changes: appointing Watson as Lead Independent Director and adopting a Director stock ownership policy to align Board interests with stockholders. Additionally, Vaxart is actively seeking stockholder approval for a reverse stock split, with voting deadline set for September 18, 2025, at 11:59 p.m. ET. The special stockholder meeting will be held virtually on September 19, 2025, at 8:30 a.m. PT.
Vaxart (OTCQX: VXRT) has reported promising Phase 1 data for its second-generation norovirus oral pill vaccine. The vaccine demonstrated a 25-fold increase in GII.4 fecal IgA response and a 10-fold increase in GI.I fecal IgA response over baseline with high-dose administration.
The second-generation constructs showed superior immunologic responses compared to first-generation versions, which previously demonstrated a 30% relative reduction in infection versus placebo in Phase 2b trials. The company's vaccine technology uniquely induces intestinal immunity, potentially offering stronger protection at the virus entry site.
With norovirus causing 685 million infections globally annually and representing a $10+ billion economic impact in the U.S., Vaxart is seeking partnerships to advance to Phase 2 trials by late 2025, with potential Phase 3 trials beginning in 2026.
Vaxart (NASDAQ:VXRT) announced the adjournment of its 2025 special meeting of stockholders to September 19, 2025. The meeting, which includes a critical reverse stock split proposal to maintain Nasdaq listing, was postponed to give shareholders more time to consider recent board changes, potential governance modifications, and upcoming company disclosures.
CEO Steven Lo emphasized the importance of maintaining Nasdaq listing for advancing the company's science and maximizing shareholder value. The virtual meeting will be accessible to stockholders of record as of July 29, 2025, who can vote until 11:59 p.m. ET on September 18, 2025.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company specializing in oral recombinant pill vaccines, has announced its participation in the upcoming H.C. Wainwright Global Investment Conference.
Management will deliver their presentation on Monday, September 8, 2025, at 12:00 PM ET. The presentation will be accessible via webcast on the company's investor relations website, with a replay available for 30 days after the event. Investors can arrange meetings with management through their H.C. Wainwright representatives.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant pill vaccines, announced the retirement of its Chairman Michael J. Finney, Ph.D. from the Board of Directors and Science and Technology Committee, effective September 30, 2025.
The Board of Directors will convene to discuss leadership succession, composition, and governance matters while considering stockholder feedback. The company aims to maintain its focus on advancing its scientific initiatives and oral pill vaccine platform development.
Vaxart (NASDAQ:VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, has received an extension from the Nasdaq Hearings Panel to regain compliance with the minimum bid price requirement. The company must meet three critical conditions: obtain stockholder approval for a reverse stock split by September 5, 2025, complete the reverse split by October 6, 2025, and demonstrate compliance with the Bid Price Rule by October 17, 2025.
During an August 14 hearing, Vaxart's management presented their compliance plan, highlighting modifications to their reverse stock split proposal, including a narrower split ratio range and reduced authorized shares. CEO Steven Lo emphasized the importance of maintaining Nasdaq listing for the company's future success.
Vaxart (OTCQX: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, will host a virtual stockholder fireside chat on August 20, 2025, at 4:30 p.m. ET to discuss its reverse stock split proposal. Leading proxy advisory firms ISS and Glass Lewis have recommended stockholders support the proposal, which aims to regain Nasdaq compliance.
The company's management team will address stockholder questions during the event, with investors able to submit questions in advance. Stockholders of record as of July 29, 2025, can vote on the proposal until September 4, 2025.
[]Vaxart (OTCQX: VXRT) reported Q2 2025 financial results and provided significant updates across its vaccine pipeline. The company reported revenue of $39.7M (vs $6.4M in Q2 2024) and a net loss of $15.0M. Key developments include positive topline data from their second-generation norovirus vaccine trial, showing statistically significant increases in blocking antibodies (141% for GI.1 and 94% for GII.4) compared to first-generation constructs.
The company's COVID-19 Phase 2b trial enrolled approximately 5,000 participants before receiving a stop work order, with follow-up continuing for all dosed participants. Vaxart ended Q2 with $26.3M in cash and equivalents, projecting runway into 2026. The company will hold a special stockholder meeting on September 5, 2025, to vote on a potential reverse stock split to regain Nasdaq compliance.